NB-4746 High dose

Preclinical

NB-4746 High dose is one of 5 therapeutic programs targeting Amyotrophic Lateral Sclerosis (ALS). It is currently in Preclinical.

Indications

Total Trials

Active Trials

Competitors

Pipeline

Status by Indication[2][1]

Indication

Amyotrophic Lateral Sclerosis (ALS)Recruiting

Amyotrophic Lateral Sclerosis (ALS)Preclinical

Recruiting

Competition

Competitive Landscape

6 competitors in Amyotrophic Lateral Sclerosis (ALS)

#DrugCompanyPhaseTrials

VHB937

Novartis

Phase 2

1 2

ALN-SOD

Regeneron

Preclinical

1 3

NB-4746 Low Dose

NNura Bio

Preclinical

1 4

MTP-101C

UUniversity of Minnesota

Preclinical

1 5

NB-4746 High dose

NNura Bio

Preclinical

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Timeline

Expected Milestones

Q1 2028

PreclinicalRecruiting

Amyotrophic Lateral Sclerosis (ALS)

NCT07369076

Clinical

Trials by Indication[1]

Amyotrophic Lateral Sclerosis (ALS)1 trial

A Phase 1b/2 Study to Evaluate NB-4746 in Participants With Amyotrophic Lateral Sclerosis.

Recruiting·NNura Bio·Preclinical·NCT07369076·80 enrolled

Sources

References

[1]
ClinicalTrials.gov — 1 trial record for NB-4746 High dose. U.S. National Library of Medicine, National Institutes of Health.
[2]
Open Targets Platform — Drug–disease associations for NB-4746 High dose. EMBL-EBI & Wellcome Sanger Institute.
[3]
SEC EDGAR — Nura Bio company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Highest Phase: Preclinical[1]
Company: NNura Bio

NB-4746 High dose

Status by Indication[2][1]

Competitive Landscape

Expected Milestones

Q1 2028

Trials by Indication[1]

Amyotrophic Lateral Sclerosis (ALS)1 trial

References

Drug Info

Quick Facts

Related News